Internal Medicine, Endocrinology, Diabetes, & Metabolism · Athens, GA
NPI
1063476364
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
700 Sunset Dr Ste 601
Athens, GA, 30606
Phone (706) 549-4155
Groups this clinician bills Medicare through
Medicare paid, 2024
$14K
295 services
Medicare patients, 2024
105
Average age 70
Drug cost, 2024
$1.2M
1,525 prescriptions
Company payments, 2025
$776
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kent J Lyon was code 99213 (office e&m - established), 65 times for 57 patients. In total Kent J Lyon billed 295 services in 20 codes, and Medicare paid $14K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-06-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 65 | 57 | $59.16 | $3,845 |
| 99214 Office E&M - Established | Office | 52 | 44 | $91.16 | $4,740 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 32 | 22 | $13.30 | $426 |
| 83036 Blood Count | Office | 30 | 24 | $9.52 | $286 |
| 95251 Test - Miscellaneous | Office | 22 | 15 | $26.37 | $580 |
| 99204 Office E&M - New | Office | 18 | 18 | $128.62 | $2,315 |
| 99203 Office E&M - New | Office | 16 | 16 | $73.62 | $1,178 |
By year: 2022 $47K for 882 services; 2023 $16K for 303 services; 2024 $14K for 295 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 30 | 24 | $9.52 | $286 |
Medicare prescription drug claims, 2024
In 2024, the drug Kent J Lyon prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 254 prescriptions and refills. In total Kent J Lyon wrote 1,525 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 254 | 267 | 58 | $271K |
| Levothyroxine Sodium Generic | 159 | 437 | 58 | $1,631 |
| Ozempic Semaglutide | 101 | 145 | 24 | $137K |
| Metformin Hcl Generic | 52 | 143 | 26 | $329 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 48 | 112 | 26 | $6,888 |
| Trulicity Dulaglutide | 46 | 68 | 15 | $66K |
| Farxiga Dapagliflozin Propanediol | 44 | 73 | 11 | $40K |
| Novolog Flexpen Insulin Aspart | 40 | 75 | 16 | $8,829 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 38 | 102 | 16 | $6,352 |
| Jardiance Empagliflozin | 38 | 62 | Under 11 | $36K |
| Methimazole Generic | 37 | 92 | 16 | $556 |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 31 | 74 | 11 | $14K |
| Gabapentin Generic | 29 | 63 | Under 11 | $471 |
| Cinacalcet Hcl Generic | 23 | 46 | Under 11 | $7,343 |
| Januvia Sitagliptin Phosphate | 22 | 54 | Under 11 | $30K |
Brand drugs: 918 claims; generic drugs: 520 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kent J Lyon $776 ($776 in general payments such as food, travel and fees) from 18 companies. The largest payer was Radius Health, Inc. with $197.
| Company | Payments | Amount |
|---|---|---|
| Radius Health, Inc. | 4 | $197 |
| Janssen Biotech, Inc. JNJ | 6 | $134 |
| Mallinckrodt Hospital Products Inc. | 3 | $75.63 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $73.25 |
| Invivyd Inc IVVD | 1 | $30.76 |
| Madrigal Pharmaceuticals MDGL | 1 | $29.39 |
| Aurinia Pharma U.S., Inc. AUPH | 1 | $28.7 |
| Insulet Corporation PODD | 1 | $25.36 |
| UCB, Inc. UCB.BR | 1 | $23.93 |
| ANI Pharmaceuticals, Inc. ANIP | 1 | $21.61 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.